Drug Profile

NB 01

Alternative Names: DA-9801; NB-01

Latest Information Update: 27 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dong-A Pharmaceutical
Developer MetaVia
Class Neuroprotectants; Phytotherapies
Mechanism of Action Nerve growth factor stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Diabetic neuropathies

Most Recent Events

18 Nov 2024 NeuroBo Pharmaceuticals is now called MetaVia
01 Aug 2024 NeuroBo Pharmaceuticals plans a phase III trial for Diabetic neuropathy in USA and South Korea
31 Jul 2023 NB 01 licensed to MThera Pharma worldwide for the treatment of Diabetic neuropathy

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com